Table 2

Univariate Cox progression-free survival analyses of various clinical parameters
Univariate analysis
Clinical Parameters P-value HR 95%CI
sunitinib vs. sorafenib 0.341 1.585 0.614-4.096
clear cell vs. papillary 0.087 2.841 0.860-9.379
nephrectomy: yes vs. no 0.620 0.725 0.203-2.590
pretreatment: yes vs. no 0.205 0.500 0.171-1.459
previous TKI: yes vs. no 0.380 0.510 0.113-2.293
previous IFN: yes vs. no 0.056 0.284 0.078-1.033
number of lesions: 1–2 vs. 3 ≥ 0.056 3.046 0.971-9.559
lung metastasis: only vs. others 0.359 0.552 0.155-1.967
bone metastasis: no vs. yes 0.927 0.942 0.264-3.365
liver metastasis: no vs. yes 0.004 7.672 1.891-31.130

Ueno et al.

Ueno et al. BMC Cancer 2012 12:162   doi:10.1186/1471-2407-12-162

Open Data